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Effect of Different Insulin Therapies 
on Obstetric-Fetal Outcomes
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María del Mar Roca-Rodríguez3, Fernando Bugatto4 & Manuel Aguilar-Diosdado1
To evaluate the effectiveness of the different insulin therapies on obstetrics-fetal outcomes in women 
with pregestational diabetes mellitus. We enrolled 147 pregnant women with pre-existing type 1 or 2 
diabetes mellitus. Clinical and biochemical parameters were analysed in relation to obstetric and fetal 
outcomes. 14.2% received treatment with Neutral Protamine Hagedorn insulin and short-acting insulin 
analogues; 19% with premixed human insulin; 40.1% with insulin glargine and lispro, 6.2% with detemir 
and aspart and 20% with continuous subcutaneous insulin infusion. All 5 types of treatment achieved a 
reduction of the mean HbA1c during pregnancy (p = 0.01). Pre-pregnancy care was carried out for 48% 
of patients. We found no statistically significant differences between the different insulin therapies 
and the obstetric-fetal outcomes. In conclusión, the different insulin therapies used in patients with 
pregestational diabetes mellitus does not seem to affect obstetric-fetal outcomes.
Diabetes mellitus is one of the most frequent metabolic complications of gestation and it is associated with an 
increased risk of maternal and fetal morbidity and mortality1. Approximately 1% of all pregnant women present 
pregestational diabetes mellitus (PGDM), however, this prevalence is increasing2. It is widely acknowledged that 
pre-pregnancy care (PPC) is beneficial for women with PGDM to minimize risks in the fetus and the mother3.
Women with PGDM present worse results than pregnant women without diabetes mellitus, with an increase 
in the rate of congenital malformations, preeclampsia, preterm birth, perinatal mortality, macrosomia4,5 and 
worsening of retinopathy and diabetic nephropathy6. Therefore, it is essential to achieve an optimum glycaemic 
control before and during gestation1.
Nowadays, insulin is the treatment of choice for PGDM, however, there is no clear evidence of a difference 
between regular human insulin and other types of insulin in gestational diabetes7. In fact, alterations in the pla-
centa and umbilical vessels in the fetus of women with gestational diabetes treated with insulin have been seen8.
Neutral Protamine Hagedorn (NPH) insulin is recommended. Several studies support the safety and effi-
cacy of insulin analogues in pregnancy9. The short-acting insulin analogues (lispro and aspart) are comparable 
in immunogenicity to rapid human insulin and they are not teratogenic. And they also achieve the objectives 
of postprandial control with lower risk of hypoglycaemia10. The long-acting insulin analogues (detemir and 
glargine) improve the fasting plasma glucose and glucose fluctuations without an increased incidence of noctur-
nal hypoglycaemia9 and they have not demonstrated significant adverse effects on outcomes of the pregnancy9,10. 
In fact, since 2012, the Food and Drug Administration (FDA) has reclassified basal insulins from category “C” to 
“B” and so they can be used in pregnancy9.
In women with type 1 PGDM, if adequate glycaemic control is not achieved with the use of multiple doses 
of insulin (MDI) in bolus-basal regimen (long-acting insulin analogues plus short-acting insulin analogues at 
each meal), the use of continuous subcutaneous insulin infusion (CSII) is recommended11. In women with type 
2 PGDM who receive oral antidiabetic treatment, they should be treated with insulin therapy during pregnancy. 
Ideally, insulin therapy should be initiated during the preconception period1.
Thus, it is important to know whether the different insulin therapies used in patients with PGDM has an 
impact on obstetrics-fetal outcomes, and whether the establishment of therapeutic and preventive strategies can 
reduce them.
The aim of the present study was to evaluate the effectiveness of the different insulin therapies on 
obstetrics-fetal outcomes and to assess the impact on maternal metabolic outcomes in relation to the PPC.
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Study Design
Study population. We enrolled 147 pregnant women for this study from among subjects who were attend-
ing the Endocrinology and Pregnancy Clinic of Puerta del Mar University Hospital (Cádiz, Spain) from February 
2007 until June 2017. The women included had a singleton gestation, pre-existing type 1 or 2 DM, clinical fol-
low-up from the first trimester of gestation until delivery. The candidates who fulfilled the selection criteria were 
informed of the characteristics and objectives of the study before they signed specially-designed informed con-
sent forms to participate in the study.
Study subjects included 113 women with type 1 PGDM and 34 with type 2 PGDM. Both groups of women 
were comparable; there was no significant difference with respect to BMI. They had the same modality of treat-
ment from the moment of inclusion of the study until delivery, only the dosage had been modified. Patients with 
type 2 PGDM received insulin treatment with short-acting insulin analogues (lispro and aspart) and NPH insulin 
or premixed human insulin, consisting of rapid-acting and intermediate-acting insulin analogues with different 
fixed-ratio mixtures of insulin preparations (for example Humalog Mix 25/50 or Novomix 30/50/70), adminis-
tered two or three times daily; or MDI; three injections of rapid-acting insulin analogues before their three main 
meals and one injection of insulin (detemir or glargine) in the morning or and in the evening (bolus basal regi-
men). Patients with type 1 PGDM received treatment with MDI in bolus-basal regimen or CSII; insulin infusion 
bolus doses of rapid-acting insulin analogues were given immediately prior to the three main meals, while the 
basal infusion of insulin was adjusted hour by hour, according to the glycaemic targets for fasting. All women in 
the continuous subcutaneous insulin infusion group started the treatment with pumps before pregnancy. Our 
clinic’s dietician prescribed individualised nutritional therapy.
Prenatal visits were performed every week until delivery. HbA1c was assessed every 4 to 6 weeks. Each woman 
had an ultrasound scan once a trimester (at about 12, 20, 34 weeks), according to the Spanish guidelines for preg-
nancy monitoring. In addition, an ultrasound scan at 32 weeks was performed to assess fetal growth.
Maternal characteristics collected included: age at conception, prepregnancy body mass index (BMI) and at 
the end of pregnancy, weight gain in pregnancy, duration of diabetes and microvascular complications at con-
ception (such as retinopathy, nephropathy, neuropathy), preconception care or not. Maternal metabolic data col-
lected were: prepregnancy HbA1c, enrolment and at the end of pregnancy, insulin requirements at the beginning 
and end of pregnancy. Maternal outcomes included progression of microvascular complications (retinography 
and albumin/creatinine ratio were performed in each trimester of pregnancy), rate of non-elective Caesarean 
section, elective Caesarean section, vaginal delivery, abortion and fetal death.
Fetal outcomes included: abdominal circumference of the fetus measured by ultrasound scan at week 32 of 
pregnancy, gestational age at birth, birth weight, newborn weight percentile, rate of preterm birth (before 37 
weeks), and macrosomia and APGAR score at 5 minutes after birth.
All biochemical parameters were analysed at the clinical laboratory of our hospital. Glucose was determined 
in venous blood using the biochemical system Modular DPD (Roche Diagnostics, Switzerland). HbA1c was 
measured in the Cobas Integra 700 autoanalyser (Roche Diagnostics, Switzerland) using an immunoturbidi-
metric method for completely haemolysed, anti-coagulated blood. The albumin/creatinine ratio was determined 
using an immunoturbidimetric test in the Cobas Integra 700 system (Roche Diagnostics, Switzerland).
Ethical approval. The study protocol was approved by the ethical committee of the University Hospital 
Puerta del Mar and followed the guidelines of the Helsinki protocol.
Statistical analysis. Descriptive statistics included mean, median, standard deviation and ranges for quan-
titative variables, and percentages for qualitative variables. Associations between categorical variables-of-interest 
and their dependent and independent variables were determined by the Mantel-Henszel χ2 test with the Yates 
correction, or the Fisher test if the variable contained <5 measurements. Parametric variables were compared 
using the Student t-test, and one-way analysis of variance (ANOVA). We used the Bonferone test, if the results 
were statistically significant. Non-parametric variables were evaluated with the Mann-Whitney test. Correlations 
between variables were evaluated using Spearman’s rank correlation coefficient. A level of p < 0.05 was accepted 
as being statistically significant. Statistical analyses were with the Statistical Package for Social Sciences (SPSS 21.0 
for Windows).
Results
Demographic, clinical and laboratory variables of the studied population are summarised in Table 1.
There were 5 types of insulin therapy; 14.2% received treatment with NPH insulin and short-acting insulin 
analogues; 19% with premixed human insulin; 40.1% with insulin glargine and lispro, 6.2% with detemir and 
aspart and 20.5% with continuous subcutaneous insulin infusion.
Ten women (7,3%) had miscarriages. Nine were type 1 PGDM; all of them had 10 or more years duration 
of diabetes and poor metabolic control prior to gestation, with HbA1c of 8%. Most of them were treated with 
glargine and lispro except for one who was treated with NPH insulin and lispro. Only one patient with type 2 
PGDM had a pre-pregnancy HbA1c of 12% and was treated with premix insulin. Five women (3.6%) had fetal 
death. Three were type 1 PGDM, one of them had twenty years duration of diabetes, a pre-pregnancy HbA1c of 
10% and mean HbA1c of 8.67%, and was treated with continuous subcutaneous insulin infusion. The other two 
fetal deaths had a mean HbA1c of 7.53% and were treated with glargine and lispro. A fetal brain malformation 
was observed in one of them. In another the fetal death was due to the development in the mother of a diabetic 
ketoacidosis and in the last case it was not possible to identify the cause of fetal death. The other patients with 
type 2 PGDM had 3 years duration of diabetes, a pre-pregnancy HbA1c of 8% and mean HbA1c of 7% and 
were treated with NPH insulin and lispro. One fetal death was due to multiple anomalies and the other was 
unexplained.
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To investigate the relationship between obstetrics and fetal outcomes and the pre-pregnancy and mean 
HbA1c, we observed that birth weight, weight percentile, end of pregnancy route and gestational age at birth were 
significantly related to pre-pregnancy and mean HbA1c during pregnancy. All data are summarized in Table 2.
The incidence of preterm birth was higher in women with a poor periconceptional HbA1c level. The 18% 
refers to spontaneous preterm birth. Most of them were medically indicated preterm birth; Caesarean in 73% 
of the cases of which 71% were emergency Caesarean - of which two were due to the development of severe 
preeclampsia, one was due to diabetic ketoacidosis in the mother and seven for induced birth following fetal 
macrosomia.
The association of different insulin therapies in PGDM, pre-pregnancy and mean HbA1c during pregnancy 
is shown in Table 3.
The relation between different insulin therapies used and the obstetric and fetal outcomes were analysed, no 
statistically significant differences were found (Table 4).
Forty-nine (48%) of pregnant women scheduled the gestation. The association of PCC and obstetrics and 
perinatal outcomes was studied. Only the gestational age at birth was statistically significant with respect PCC (P 
value = 0.04).
With regard to progression of maternal microvascular complications during pregnancy, four patients (2.9%) 
had progression of nephropathy and twenty-three (16.3%) had progression of retinopathy. The association of 
different insulin therapies and progression of maternal microvascular complications were not significant (results 
not shown).
Type 1 PGDM Type 2 PGDM p
Maternal age; years 30.3 +/− 4.9 31.2 +/− 4.7 0.3
Duration of diabetes; years 16.1 +/− 6.6 3.9 +/− 2.1 0.001
Pre-pregnancy care; N(%) 40 (35%) 9 (26%) 0.01
Micro-vascular complications at conception;
Retinopathy; N(%) 41 (40%) 2 (6%) 0.001
Nephropathy; N% 21(18%) 0 0.05
Pre-pregnancy body mass index (BMI); kg/m2 24.3 +/− 2.8 25.7 +/− 3.6 0.06
BMI at the end of pregnancy; kg/m2 30.1 +/− 2.6 30.4 +/− 2.7 0.6
Weight gain in pregnancy; Kg 3.9 +/− 1.3 4.6 +/− 1.2 0.09
Pre-pregnancy HbA1c; % 7.6 +/− 1.4 7.0 +/− 1.6 0.08
Mean HbA1c in pregnancy; % 6.7 +/− 1.0 6.1 +/− 0.8 0.05
Insulin requirements at the beginning of pregnancy; UI/Kg 0.7 +/− 0.2 0.4 +/− 0.2 0.01
Insulin requirements at the end of pregnancy; UI/Kg 0.8 +/− 0.2 0.6 +/− 0.2 0.01
Table 1. Demographic, clinical and laboratory variables in type 1 PGDM and type 2 PGDM. Values are given as 
mean +/− SD or number of subjects (n) with percentage in parenthesis.
Obstetric and fetal outcomes
Pre-pregnancy 
HbA1c
Mean HbA1c in 
pregnancy
Fetal abdominal circumference by 
ultrasound scan at week 32 of pregnancy P = 0.5 P = 0.4
- High range (>298 mm) 7.7 +/− 1.7 6.5 +/− 0.8
- Normal range (<298 mm) 6.9 +/− 1.4 6.4 +/− 0.9
Birth weight P = 0.2 P = 0.04
− <2500 g 7.4 +/− 1.6 6.2 +/− 0.8
− 2500–3999 g 7.1 +/− 1.5 6.3 +/− 0.9
− >4000 g 7.8 +/− 1.7 6.7 +/− 0.9
Weight percentile P = 0.007 P = 0.001
- Normal weight 6.7 +/− 1.6 6.1 +/− 0.8
- Macrosomia 7.2 +/− 1.6 6.7 +/− 0.9
End of Pregnancy Route P = 0.01 P = 0.001
- Vaginal birth 6.8 +/−1.4 6.1 +/− 0.7
- Elective Cesarean 7.0 +/− 1.5 6.5 +/− 1.0
- Non- Elective Cesarean 7.7 +/− 1.6 6.5 +/− 0.8
- Miscarriage 8.2 +/− 1.8 7.9 +/− 1.9
- Fetal death 8.5 +/− 1.1 7.5 +/− 0.7
Gestational age at birth P = 0.01 P = 0.001
- Preterm birth 7.8 +/− 1.5 7.1 +/− 1.3
- Birth to term 7.0 +/− 1.6 6.2 +/− 0.8
Table 2. Relationship between obstetric and fetal outcomes and pre-pregnancy and mean HbA1c in pregnancy.
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Discussion
The goal of glycaemic control in pregnancy is to reach a value of Hab1c as close to the normal range, without 
hypoglycaemia1. In order to achieve this goal, in addition to complying with adequate hygienic and dietary hab-
its, an adjustment of the insulin treatment, using the model of insulin therapy in an individualised way to the 
characteristics of each patient, is required6. Our patients had a mean HbA1c of 6.53 +/− 1.05%; we observed an 
improvement of the metabolic control throughout the gestation, regardless of the type of insulin treatment. Our 
data confirm other reports10.
Observational studies show that an HbA1c greater than 1% of the normal range is associated with a higher 
rate of congenital anomalies and miscarriages with respect to the general population12. The rate of miscarriages in 
our series was 7.3%. In other series with scheduled pregnancies it was 5.7%13 and with unscheduled pregnancies 
from 14%3. As we have already mentioned, all miscarriages occurred in patients with 10 or more years of duration 
of DM and poor metabolic control. Results confirm other studies that have shown that poor metabolic control in 
early gestation, especially during embryogenesis, is related to a higher incidence of miscarriages and congenital 
anomalies14,15. With respect to fetal deaths, we had 3,6%. Results confirm other studies12.
The pre-pregnancy HbA1c of our pregnant women was 7.3 +/− 1.58%, higher levels than those recom-
mended5, which coincides with the fact that there were a small number of scheduled pregnancies. It is clear that 
obtaining pre-pregnancy optimum metabolic control is of great importance. However, only 28% of pregnant 
women scheduled their gestation. In other series 75% of gestations were unscheduled12. This could be attributed 
to the fact that in our study we also evaluated patients with type 2 PGDM, who may have had less knowledge 
about their disease and the impact on gestation. Pre-pregnancy glycaemic control plays a fundamental role in 
reducing the frequency of fetal outcomes. When we analysed the relationship between pre-pregnancy HbA1c 
and obstetrics and perinatal outcomes, we found weight percentile, end of pregnancy route and gestational age at 
birth were statistically significant. Therefore, a better pre-pregnancy metabolic control improves the incidence of 
preterm delivery, which is consistent with what has already been published16.
The majority of our patients with type 2 PGDM received insulin treatment with short-acting insulin ana-
logues and NPH or premixed human insulin, while our patients with type 1 DMPG received treatment with MDI 
(glargine and lispro more frequently) or CSII. Currently there are many options for insulin treatment in pregnant 
patients. Until now the recommended treatment has been short-acting insulin analogues and NPH17. After recog-
nizing the safety and efficacy of insulin analogues9, it is possible to treat with long-acting analogues, especially if 
there is a risk of nocturnal hypoglycaemia18,19. However, there are no studies that clearly demonstrate the benefits 
over the rest of insulin therapies and extensive clinical experience with long-acting analogues is required20,21. 
With respect to treatment with CSII, some studies have specifically compared treatment with MDI vs. CSII22,23. 
There are studies where CSII therapy was more effective in improving the mean HbA1c and glycaemia than 
MDI therapy23,24. But in more recent studies, although mean blood glucose was lower with CSII, no differences 
were observed with respect to HbA1c25. In our study, there were no differences with respect to metabolic control 
among patients treated with MDI or CSII. In a recent Cochrane review26, it was concluded that there is no evi-
dence that show that the use of one particular form of insulin administration is better than another in pregnant 
women with diabetes.
Poor metabolic control during gestation is associated with a higher prevalence of macrosomia4. In our study, 
the lower the mean HbA1c during pregnancy, the lower the percentage of caesarean sections, macrosomia, abor-
tions and fetal deaths. Data confirm what is described in the literature4,27.
We also analysed the insulin therapeutic modality used, with the progression of microvascular maternal com-
plications during pregnancy. In our study we observed a progression of retinopathy of 16.3%, a percentage similar 
to other studies that have shown a progression of diabetic retinopathy between 20 and 55%28. However, this is 
not easily comparable because it would be necessary to differentiate type 1 from type 2 DM, in order to affirm 
a smaller progression of complications in our series. In diabetic nephropathy, there are no conclusive studies in 
this respect. In our patients we observed a progression of nephropathy of 2.9%. 14.5% had microalbuminuria 
and 6.9% had nephropathy before gestation. These data coincide with what has been published, with a prevalence 
of approximately 11% of microalbuminuria and 5% of nephropathy29. Two large studies of women with type 




Mean HbA1c in 
pregnancy%
a) Type 1 PGDM
NPH and short-acting insulin analogues 7.8 +/− 1.1 6.9 +/− 0.9*
Glargine and Lispro 7.6 +/− 1.4 6.6 +/− 0.7*
Detemir and Aspart 8.3 +/− 0.7 7.04 +/− 0.7*
CSII 7.4 +/− 1.3 6.6 +/− 0.8*
b) Type 2 PGDM
NPH and short-acting insulin analogues 7.8 +/− 1.1 6.9 +/− 0.9*
Premixed human insulin 6.2 +/− 1.4 5.6 +/− 0.5*
Glargine and Lispro 7.4 +/− 0.8 6.8 +/− 0.3*
Detemir and Aspart 7.1 +/− 1.1 6.1 +/− 0.8*
Table 3. Effectiveness of different insulin therapies on HbA1c levels. NPH; Neutral Protamine Hagedorn, CSII; 
continuous subcutaneous insulin infusion. *p < 0.05. NPH; Neutral Protamine Hagedorn, *p < 0.05.
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Complications Trial), concluded that gestation is not a risk factor for the development of retinopathy, nephrop-
athy or early neuropathy after correction of confounding factors such as age, duration of diabetes and HbA1c28.
These results are limited and still inconclusive because the study compares the effectiveness of different insulin 
therapies in patients with PGDM and does not discriminate subcategories of PGDM (type 1 and type 2 DM). In 
addition well-designed randomised clinical trials are needed to draw a conclusion.
Conclusion
The different insulin therapies used in patients with PGDM does not seem to affect obstetric and fetal outcomes. 
Poor glycaemic control prior to and during gestation is associated with poor obstetric-fetal outcomes. Patients 
who have PPC have a lower HbA1c and a reduction of obstetric and fetal outcomes. Further specifically designed 
studies are needed to evaluate metabolic, obstetric and fetal outcomes depending on different insulin treatment 
used.
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